FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589592854> ?p ?o ?g. }

• W2589592854 endingPage "634" @default.
• W2589592854 startingPage "634" @default.
• W2589592854 abstract "634 Background: In the treatment for mCRC, it is essential for understanding the prognosis of each individual patient. Köhne’s index (KI) based on performance status, white blood cell count, alkaline phosphatase and number of metastatic sites has been previously proposed. However, in the salvage setting, the validity of KI has not been reported in patients treated by cetuximab-based chemotherapy. Methods: 269 patients with mCRC treated by cetuximab contained chemotherapy were retrospectively registered from 27 centers in Japan. This analysis was included in the KRAS wild-type patients who were refractory to or intolerant for 5-FU/irinotecan/oxaliplatin and were never administered anti-EGFR-antibody. Univariate and multivariate analysis for overall survival were performed using patient characteristics. Survival analyses were performed with Kaplan-Meier method, log-rank test and Cox proportional hazards model. The analysis was also designed to determine whether the Köhne’s classification could be extended to other endpoints such as progression-free survival. Results: All data were available for prognostic categorization in 127 patients. Median overall and progression-free survival was 9.8 and 4.2 months. The distribution and median survival / progression-free survival for KI were as follows: low risk (L) (n = 40; 13.1/5.1 months), intermediate risk (I) (n = 17; 9.6/3.5 months), and high risk (H) (n = 70; 7.6/4.1 months). For overall survival, there was significant difference between L and H (p = 0.004), but not between L and I (p = 0.213), and between I and H (p = 0.321). For progression-free survival, there was tended to difference between L and H (p = 0.083), but not between L and I (p = 0.392), and between I and H (p = 0.630). In Cox multivariate analysis, KI showed an independent prognostic impact (HR 1.370, p = 0.010), but not predictive impact (HR 1.147, p = 0.212). Conclusions: In this analysis, KI might be a prognostic factor in salvage treatment with cetuximab-based regimen, but no effect predicted impact. Moreover, the prospective evaluation is needed for the further validation." @default.
• W2589592854 created "2017-03-03" @default.
• W2589592854 creator A5014153766 @default.
• W2589592854 creator A5015023308 @default.
• W2589592854 creator A5023464025 @default.
• W2589592854 creator A5026866129 @default.
• W2589592854 creator A5027875109 @default.
• W2589592854 creator A5037372375 @default.
• W2589592854 creator A5038808540 @default.
• W2589592854 creator A5047037093 @default.
• W2589592854 creator A5048421476 @default.
• W2589592854 creator A5048919337 @default.
• W2589592854 creator A5054182211 @default.
• W2589592854 creator A5056456991 @default.
• W2589592854 creator A5060570178 @default.
• W2589592854 creator A5064684165 @default.
• W2589592854 creator A5077427280 @default.
• W2589592854 creator A5080086760 @default.
• W2589592854 creator A5080229788 @default.
• W2589592854 creator A5084976321 @default.
• W2589592854 creator A5087222002 @default.
• W2589592854 creator A5090905175 @default.
• W2589592854 date "2014-01-20" @default.
• W2589592854 modified "2023-09-27" @default.
• W2589592854 title "Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901." @default.
• W2589592854 doi "https://doi.org/10.1200/jco.2014.32.3_suppl.634" @default.
• W2589592854 hasPublicationYear "2014" @default.
• W2589592854 type Work @default.
• W2589592854 sameAs 2589592854 @default.
• W2589592854 citedByCount "0" @default.
• W2589592854 crossrefType "journal-article" @default.
• W2589592854 hasAuthorship W2589592854A5014153766 @default.
• W2589592854 hasAuthorship W2589592854A5015023308 @default.
• W2589592854 hasAuthorship W2589592854A5023464025 @default.
• W2589592854 hasAuthorship W2589592854A5026866129 @default.
• W2589592854 hasAuthorship W2589592854A5027875109 @default.
• W2589592854 hasAuthorship W2589592854A5037372375 @default.
• W2589592854 hasAuthorship W2589592854A5038808540 @default.
• W2589592854 hasAuthorship W2589592854A5047037093 @default.
• W2589592854 hasAuthorship W2589592854A5048421476 @default.
• W2589592854 hasAuthorship W2589592854A5048919337 @default.
• W2589592854 hasAuthorship W2589592854A5054182211 @default.
• W2589592854 hasAuthorship W2589592854A5056456991 @default.
• W2589592854 hasAuthorship W2589592854A5060570178 @default.
• W2589592854 hasAuthorship W2589592854A5064684165 @default.
• W2589592854 hasAuthorship W2589592854A5077427280 @default.
• W2589592854 hasAuthorship W2589592854A5080086760 @default.
• W2589592854 hasAuthorship W2589592854A5080229788 @default.
• W2589592854 hasAuthorship W2589592854A5084976321 @default.
• W2589592854 hasAuthorship W2589592854A5087222002 @default.
• W2589592854 hasAuthorship W2589592854A5090905175 @default.
• W2589592854 hasConcept C10515644 @default.
• W2589592854 hasConcept C121608353 @default.
• W2589592854 hasConcept C126322002 @default.
• W2589592854 hasConcept C141071460 @default.
• W2589592854 hasConcept C143998085 @default.
• W2589592854 hasConcept C144301174 @default.
• W2589592854 hasConcept C207103383 @default.
• W2589592854 hasConcept C2776694085 @default.
• W2589592854 hasConcept C2778336483 @default.
• W2589592854 hasConcept C2779998722 @default.
• W2589592854 hasConcept C2780259306 @default.
• W2589592854 hasConcept C2780739268 @default.
• W2589592854 hasConcept C2780775027 @default.
• W2589592854 hasConcept C2780962732 @default.
• W2589592854 hasConcept C2781187634 @default.
• W2589592854 hasConcept C2781413609 @default.
• W2589592854 hasConcept C38180746 @default.
• W2589592854 hasConcept C44249647 @default.
• W2589592854 hasConcept C50382708 @default.
• W2589592854 hasConcept C526805850 @default.
• W2589592854 hasConcept C66339696 @default.
• W2589592854 hasConcept C71924100 @default.
• W2589592854 hasConceptScore W2589592854C10515644 @default.
• W2589592854 hasConceptScore W2589592854C121608353 @default.
• W2589592854 hasConceptScore W2589592854C126322002 @default.
• W2589592854 hasConceptScore W2589592854C141071460 @default.
• W2589592854 hasConceptScore W2589592854C143998085 @default.
• W2589592854 hasConceptScore W2589592854C144301174 @default.
• W2589592854 hasConceptScore W2589592854C207103383 @default.
• W2589592854 hasConceptScore W2589592854C2776694085 @default.
• W2589592854 hasConceptScore W2589592854C2778336483 @default.
• W2589592854 hasConceptScore W2589592854C2779998722 @default.
• W2589592854 hasConceptScore W2589592854C2780259306 @default.
• W2589592854 hasConceptScore W2589592854C2780739268 @default.
• W2589592854 hasConceptScore W2589592854C2780775027 @default.
• W2589592854 hasConceptScore W2589592854C2780962732 @default.
• W2589592854 hasConceptScore W2589592854C2781187634 @default.
• W2589592854 hasConceptScore W2589592854C2781413609 @default.
• W2589592854 hasConceptScore W2589592854C38180746 @default.
• W2589592854 hasConceptScore W2589592854C44249647 @default.
• W2589592854 hasConceptScore W2589592854C50382708 @default.
• W2589592854 hasConceptScore W2589592854C526805850 @default.
• W2589592854 hasConceptScore W2589592854C66339696 @default.
• W2589592854 hasConceptScore W2589592854C71924100 @default.
• W2589592854 hasIssue "3_suppl" @default.
• W2589592854 hasLocation W25895928541 @default.
• W2589592854 hasOpenAccess W2589592854 @default.

• next